Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

Although there are a growing number of well-reported, late-stage clinical trial failures in Alzheimer’s disease, the introduction of a disease-modifying therapy within the next 5 years may be anticipated. These treatments are likely to target Alzheimer’s disease in the earlier disease stages, unlike...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouvy, Jacoline C., Jonsson, Pall, O’Rourke, Diana, Chadha, Antonella Santuccione, Hedberg, Niklas, Makady, Amr, Xoxi, Entela, Wied, Christine Gispen-de, Schiel, Anja, Long, Raj, Gallacher, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280845/
https://www.ncbi.nlm.nih.gov/pubmed/30467744
http://dx.doi.org/10.1007/s40263-018-0581-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280845/
https://www.ncbi.nlm.nih.gov/pubmed/30467744
http://dx.doi.org/10.1007/s40263-018-0581-x

Ejemplares similares